Skip to main content

Table 3 Prognostic factors by univariate and multivariate analyses

From: Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A)

 Pre-PSMPost-PSM
univariate analysesmultivariate analysesmultivariate analyses
PHR(95% CI)PHR(95% CI)PHR(95% CI)
Gender0.1840.886 (0.742–1.059)    
Age0.4181.008 (0.989–1.028)
ECOG0.7961.013 (0.921–1.113)
Hypertension0.9991.000 (0.834–1.199)
Cardiovascular disease0.8061.032 (0.805–1.323)
Pulmonary disease0.7951.038 (0.782–1.379)
Diabetes0.0361.326 (1.019–1.726)0.0441.314 (1.007–1.714)0.0281.643 (1.056–2.555)
Tumor location0.0061.160 (1.044–1.289)0.0041.174 (1.052–1.311)  
Primary tumor length0.0011.063 (1.024–1.102)  
Primary tumor volume< 0.0011.063 (1.024–1.102)0.0261.003 (1.000–1.006)
Clinical T stage0.0011.207 (1.079–1.351)0.0281.146 (1.015–1.295)0.0281.270 (1.026–1.571)
Clinical N stage0.0011.351 (1.131–1.613)0.0231.237 (1.030–1.485)0.0011.673 (1.223–2.287)
Clinical M stage< 0.0011.825 (1.308–2.545)0.0021.703 (1.209–2.399)0.0011.965 (1.295–2.983)
GTV dose1.3981.000 (1.000–1.000)    
Technique0.6760.964 (0.811–1.146)
Treatment pattern0.8541.022 (0.811–1.288)
Short-term response to RT0.0011.263 (1.095–1.457)0.0031.243 (1.076–1.435)
  1. PSM Propensity score matching
  2. ECOG Eastern Cooperative Oncology Group scoring